StockData

Serina Therapeutics vs Soligenix

SER and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SER and SNGX compare

Serina Therapeutics is the larger company, worth 5.7 times as much as Soligenix ($34.7M against $6.1M).

Soligenix scores higher on the StockData Score (6 against 2 for Serina Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSERSNGX
Size and price
Market cap$34.7M$6.1M
Share price$1.36$0.281
Change, 1 year−66.6%−79.5%
Change, 5 years−94.6%−99.9%
Beta (5Y)1.502.38
Employees1614
StockData Score
Total score26 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/B–0.9×
FCF yield−61.1%–
Growth
Revenue growth, 5Y average−18.5%–
Profitability
Return on equity−1175%−242% (better)
Financial health
Debt / equity–0.00
Current ratio6.65 (better)2.77
Altman Z-score−0.24 (better)−35.09
Piotroski F-score33
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.5%4.3%
Held by insiders49.7%0.69%
Insider net buying, 12 months−$232K–
Short interest, % of float0.37%0.31%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.